US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings
HOUSTON, June 02, 2008 /PRNewswire/ -- Physicians affiliated with the US Oncology Research Network are presenting the results of their clinical research at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) held May 30 - June 3, 2008 in Chicago.
Dr. Joyce O'Shaughnessy of Texas Oncology-Baylor Charles A Sammons Cancer Center, an affiliate of US Oncology, gave an oral presentation on findings from a randomized Phase III trial that studied lapatanib (L) alone and in combination with trastuzumab (T) in patients with HER2+ metastatic breast cancer who progressed on trastuzumab. The research is the largest study of two targeted agents in HER2+ metastatic breast cancer and the first to demonstrate the synergy of lapatanib and trastuzumab in a Phase III setting.
The research found that improved clinical outcome was achieved with the combination of L+T in patients progressing on T-based therapy and without substantial change in the side-effect profile. The role of combined anti-HER2 therapy, in combination with chemotherapy, in less heavily pretreated patients with early stage disease is ongoing in the Adjuvant L and/or T Treatment Optimization (ALTTO) study.
"More complete HER2 blockade with lapatinib and trastuzumab benefits patients whose metastatic breast cancer (MBC) is progressing in spite of trastuzumab therapy," said Dr. O'Shaughnessy. "This combination is an important new therapeutic strategy for HER2+ MBC patients, one that does not contain chemotherapy. This combination also has exciting potential as treatment for early stage breast cancer, a hypothesis that is being evaluated now in the global ALTTO trial." Dr. O'Shaughnessy serves as co-chair of the US Oncology Breast Cancer Research Committee and associate director for clinical research for US Oncology.
In addition to Dr. O'Shaughnessy's presentation, physicians affiliated with US Oncology participated in 23 oral and poster presentations and published studies at this year's ASCO conference. Findings were presented on a variety of disease states including breast, lung, genitourinary, gynecologic, and melanoma.
Breast -- Nicholas Robert, M.D., Fairfax-Northern Virginia Hematology-Oncology, co-chair US Oncology Breast Cancer Research Committee: Results of a Phase II study of pemetrexed as first-line chemotherapy for advanced or metastatic breast cancer -- Michael Danso, M.D., Virginia Oncology Associates: Phase II trial of weekly administration of nabpaclitaxel in combination with bevacizumab in women with metastatic breast cancer (MBC) -- Mary Ann Allison, M.D., Comprehensive Cancer Centers of Nevada-Siena and Joanne Blum, M.D., Ph.D., Texas Oncology-Baylor Charles A Sammons Cancer Center: Phase II study of eribulin mesylate in patients with locally advanced or metastatic breast cancer (MBC) previously treated with an anthracycline, taxane, and capecitabine -- Sasha Vukelja, M.D., Texas Oncology-Tyler: Phase II and Phase III study of the efficacy of nab-paclitaxel in patients with poor prognostic factors or with anthracycline-resistant metastatic breast cancer (MBC) -- Frankie Holmes, M.D., Texas Oncology-Houston Memorial City, US Oncology network associate chair Breast Cancer Research Committee,: Phase II study on transcriptional profiles of triple receptor-negative breast cancer: Are Caucasian, Hispanic and African-American different? Lung -- Charles Weissman, M.D., New York Oncology-Hematology--Latham: Phase III open-label comparison of gemcitabine/oxaliplatin versus paclitaxel/carboplatin as first-line therapy for advanced non-small cell lung cancer (NSCLC) Genitourinary -- Guru Sonpavde, M.D., Texas Oncology-Deke Slayton Cancer Center: Phase II study of Azacitidine for castration-resistant prostate cancer progressing on combined androgen blockade -- Phillip Periman, M.D., Texas Oncology-Amarillo: Phase II study of Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy -- Allen Cohn, M.D., Rocky Mountain Cancer Centers-Midtown, co-chair, US Oncology GI Cancer Research Committee: Phase III Panitumumab (pmab) regimen evaluation in colorectal cancer to estimate primary response to treatment (PRECEPT): effect of KRAS mutation status on second-line treatment (tx) with pmab and FOLFIRI -- Thomas Hutson, D.O., PharmD, Texas Oncology-Baylor Charles A Sammons Cancer Center, associate chair, US Oncology GU Cancer Research Committee,: RAD001 plus best supportive care (BSC) vs BSC plus placebo in patients with metastatic renal cell carcinoma (RCC), which has progressed on VEGF-TKI therapy: results from a randomized, double-blind, multicenter Phase III study; Phase III randomized study of overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC); Multicenter, Phase I/II study of sunitinib in combination with docetaxel and prednisone in patients with metastatic castrate-resistant prostate cancer (mCRPC)-preliminary results; Biomarker analysis and final results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor; A multicenter, prospective Phase II trial of sorafenib in patients (Pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab -- Kelly Pendergrass, M.D., Kansas City Cancer Center-South: Characterization of hyperglycemia, hypercholesterolemia, and hyperlipidemia in patients with advanced renal cell carcinoma treated with temsirolimus or interferon Gynecologic -- Michael Teneriello, M.D., Texas Oncology-Austin Central, co-chair, US Oncology Gynecologic Cancer Research Committee: Phase III trial of induction gemcitabine (G) or paclitaxel (T) plus carboplatin (C) followed by elective T consolidation in advanced ovarian cancer (OC): Interim analysis of induction chemotherapy Melanoma -- William Stephenson, M.D., Kansas City Cancer Center-South: PhaseI/II study of imexon (AMP) plus dacarbazine (DTIC) in patients (Pts) with metastatic malignant melanoma Leukemia -- Roger Lyons, M.D., Cancer Care Centers of South Texas-Medical Center: Phase II study of single agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy Solid Tumors -- William Stephenson, M.D., Kansas City Cancer Center-South: Phase I study multicenter study to assess the safety, tolerability, and pharmacokinetics of AZD4877 administered twice weekly in adult patients with advanced solid malignancies -- Robert Raju, M.D., Dayton Oncology & Hematology-Kettering: An open label Phase I dose escalation study of ADH-1 in combination with chemotherapy in subjects with N-Cadherin expressing solid tumors Lymphoma and Plasma Cell Disorders -- Alan Feiner, M.D., Rocky Mountain Cancer Centers-Rose, and John Mattern, D.O., Virginia Oncology Associates-Newport News: Primary therapy of Waldenstrom's macroglobulinemia with bortezomib, dexamethasone and rituximab: results of WMCTG Clinical Trial 05-180
About US Oncology Research
The US Oncology Research network is an established community-based research operation specializing in all phases of cancer clinical trials. The research network currently has 595 physicians actively enrolling patients, 109 research sites, and is currently involved in 63 open research trials. The network has contributed to the development of 24 of 30 of the latest cancer-fighting drugs approved by the Food and Drug Administration for use. Since 1993, more than 32,000 patients have participated in clinical trials managed by US Oncology network practices. For more information, visit the "Research" section under "Our Services" on the company's Web site, http://www.usoncology.com.
About US Oncology, Inc.
US Oncology, headquartered in Houston, works closely with physicians, manufacturers and payers to identify and deliver innovative services that enhance patient access to advanced cancer care. US Oncology supports one of the nation's foremost cancer treatment and research networks accelerating the availability and use of evidence-based medicine and shared best practices.
US Oncology's expertise in supporting every aspect of the cancer care delivery system -- from drug development to treatment and outcomes measurement, enables the company to help increase the efficiency and safety of cancer care. According to the company's last quarterly earnings report, US Oncology is affiliated with 1,247 physicians operating in 472 locations, including 91 radiation oncology facilities in 39 states. For more information, visit the company's Web site, http://www.usoncology.com.
CONTACT: Lisa Henderson, +1-813-775-6208,, for US Oncology, Inc. Lisa.Henderson@hillandknowlton.com
Web site: http://www.usoncology.com/
Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: June 2008